



Provider communication

General information and system updates

July 25, 2024

Humira Biosimilars - Formulary Change

Applies to: Mercy Care ACC-RBHA, Mercy Care DD, Mercy Care Long Term Care, and Mercy DCS CHP

Effective **August 1, 2024**, Humira will become non preferred. **Simlandi, Hadlima** and **adalimumab-adbm** will be the preferred biosimilars and will require prior authorization. Simlandi and Hadlima are available at CVS Specialty Pharmacy and adalimumab-adbm will be available at participating network pharmacies.

Members that are currently receiving Humira through the pharmacy benefit will not need a new Prior Authorization for any of the preferred biosimilars.

Our complete formulary is available on our website at [Pharmacy Benefits | Mercy Care Providers \(mercycareaz.org\)](http://www.mercycareaz.org). Thank you for your cooperation. We appreciate the opportunity to work with you to deliver clinically appropriate health care that is also cost-effective.

As always, don't hesitate to contact your [Mercy Care Network Management Representative](#) with any questions or comments. You can find this notice and all other provider notices on our [Mercy Care website](#).

Thanks for all you do!